Should I buy or sell Asensus Surgical stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asensus Surgical in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ASXC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASXC, but not buy additional shares or sell existing shares. View ASXC analyst ratings or view top-rated stocks .

What is Asensus Surgical's stock price target for 2024?

2 analysts have issued 12 month price targets for Asensus Surgical's stock. Their ASXC share price targets range from $0.35 to $1.00. On average, they expect the company's stock price to reach $0.68 in the next year. This suggests a possible upside of 167.1% from the stock's current price. View analysts price targets for ASXC or view top-rated stocks among Wall Street analysts .

When is Asensus Surgical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ASXC earnings forecast .

How were Asensus Surgical's earnings last quarter?

Asensus Surgical, Inc. (NYSEAMERICAN:ASXC) released its earnings results on Thursday, March, 21st. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The company had revenue of $5.43 million for the quarter. Asensus Surgical had a negative net margin of 914.46% and a negative trailing twelve-month return on equity of 135.94%.

How do I buy shares of Asensus Surgical?

Shares of ASXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:ASXC

Asensus Surgical (ASXC) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free ASXC Stock Alerts

$0.25

-0.01 (-3.81%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.25
▼
$0.26
50-Day Range: N/A
52-Week Range: $0.20
▼
$0.86

Volume: 958,976 shs
Average Volume: 1.57 million shs
Market Capitalization: $68.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $0.68

Stock Analysis Analyst Forecasts Chart Earnings Headlines Insider Trades Ownership Short Interest

Get Asensus Surgical alerts:

Asensus Surgical MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 167.1% Upside
$0.68 Price Target
Short Interest: Bearish
6.66% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.19) to ($0.13) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.30 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
Asensus Surgical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Asensus Surgical has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
6.66% of the float of Asensus Surgical has been sold short.
Short Interest Ratio / Days to Cover
Asensus Surgical has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Asensus Surgical has recently increased by 4.35%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Asensus Surgical does not currently pay a dividend.
Dividend Growth
Asensus Surgical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ASXC.

0.6

News and Social Media Coverage

Search Interest
5 people have searched for ASXC on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Asensus Surgical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Asensus Surgical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.87% of the stock of Asensus Surgical is held by insiders.
Percentage Held by Institutions
Only 9.35% of the stock of Asensus Surgical is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Asensus Surgical are expected to grow in the coming year, from ($0.19) to ($0.13) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Asensus Surgical is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Asensus Surgical is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Asensus Surgical has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

Click here to see Louis' new video for yourself.

About Asensus Surgical Stock (NYSEAMERICAN:ASXC)

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

ASXC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ASXC Stock News Headlines

April 4, 2024 | markets.businessinsider.com

Wayfair To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Thursday

April 3, 2024 | bizjournals.com

Billion-dollar firm moves to buy RTP outfit in need of capital

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

April 3, 2024 | markets.businessinsider.com

Asensus Surgical Agrees To Karl Storz's Acquisition Offer; Stock Up

April 3, 2024 | investorplace.com

Small Packages, Big Gains: 3 Penny Stocks to Buy as Q2 Kicks Off

April 3, 2024 | msn.com

Asensus Surgical gains after Germany-based KARL STORZ announces buyout bid

April 3, 2024 | globenewswire.com

Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG

March 26, 2024 | finance.yahoo.com

ASXC Oct 2024 0.500 put

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

March 22, 2024 | benzinga.com

Asensus Surgical Earnings Preview

March 22, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Asensus Surgical Amidst Growth and Expansion Prospects

March 22, 2024 | msn.com

Asensus Surgical, Inc. (AMEX:ASXC) Q4 2023 Earnings Call Transcript

March 21, 2024 | markets.businessinsider.com

ASXC Stock Earnings: Asensus Surgical Beats EPS, Beats Revenue for Q4 2023

March 21, 2024 | benzinga.com

Recap: Asensus Surgical Q4 Earnings

March 21, 2024 | msn.com

Asensus Surgical Non-GAAP EPS of -$0.07 misses by $0.02, revenue of $5.43M misses by $0.04M

March 21, 2024 | markets.businessinsider.com

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023

March 21, 2024 | globenewswire.com

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023

March 21, 2024 | msn.com

Options Volatility and Implied Earnings Moves Today, March 21, 2024

March 15, 2024 | globenewswire.com

Asensus Surgical, Inc. Schedules Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call for March 21, 2024

March 7, 2024 | nz.finance.yahoo.com

Asensus Surgical Inc (2TX.DU)

February 28, 2024 | globenewswire.com

Asensus Surgical to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

February 27, 2024 | globenewswire.com

Asensus Surgical Celebrates 1,000 Senhance Cases Completed at Three Global Hospitals

February 22, 2024 | benzinga.com

Asensus Surgical Stock (OTC:TRXDW) Dividends: History, Yield and Dates

February 6, 2024 | finance.yahoo.com

Down -25.24% in 4 Weeks, Here's Why Asensus Surgical (ASXC) Looks Ripe for a Turnaround

January 16, 2024 | finanznachrichten.de

Asensus Surgical, Inc.: Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery Program

January 16, 2024 | finance.yahoo.com

Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery Program

January 8, 2024 | finance.yahoo.com

Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA

See More Headlines

Receive ASXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Asensus Surgical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:ASXC
CUSIP: N/A
CIK: N/A
Web: www.asensus.com
Phone: (919) 765-8400
Fax: 919-765-8459
Employees: 207
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $0.68
High Stock Price Target: $1.00
Low Stock Price Target: $0.35
Potential Upside/Downside: +160.8%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-78,430,000.00
Net Margins: -914.46%
Pretax Margin: -910.80%
Return on Equity: -135.94%
Return on Assets: -98.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.88
Quick Ratio: 2.31

Sales & Book Value

Annual Sales: $8.58 million
Price / Sales: 8.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.13 per share
Price / Book: 1.99

Miscellaneous

Outstanding Shares: 271,990,000
Free Float: 264,180,000
Market Cap: $70.39 million
Optionable: Not Optionable
Beta: 1.43

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Anthony Fernando (Age 52)
President, CEO & Director
Comp: $901.03k
Mr. Shameze Rampertab B.Sc. MBA (Age 57)
CA, CPA, Executive VP & CFO
Comp: $511.25k
Mr. Joshua B. Weingard (Age 51)
Chief Legal Officer & Secretary
Mr. Paul Ziegler Jr. (Age 50)
J.D., Vice President of Sales
Mr. Ethan Loiselle
Vice President of Global Marketing
Ms. Amanda Owens
Vice President of People
Mr. Ravi Kommineni
Head of Global Quality & Regulatory
Mr. Motti Frimer
Vice President of R&D, Digital Solutions and MD of Asensus Surgical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ASXC Stock Analysis - Frequently Asked Questions

Should I buy or sell Asensus Surgical stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asensus Surgical in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ASXC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASXC, but not buy additional shares or sell existing shares.
View ASXC analyst ratings or view top-rated stocks.
What is Asensus Surgical's stock price target for 2024?: 2 analysts have issued 12 month price targets for Asensus Surgical's stock. Their ASXC share price targets range from $0.35 to $1.00. On average, they expect the company's stock price to reach $0.68 in the next year. This suggests a possible upside of 167.1% from the stock's current price.
View analysts price targets for ASXC or view top-rated stocks among Wall Street analysts.
When is Asensus Surgical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ASXC earnings forecast.

How were Asensus Surgical's earnings last quarter?: Asensus Surgical, Inc. (NYSEAMERICAN:ASXC) released its earnings results on Thursday, March, 21st. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The company had revenue of $5.43 million for the quarter. Asensus Surgical had a negative net margin of 914.46% and a negative trailing twelve-month return on equity of 135.94%.
How do I buy shares of Asensus Surgical?: Shares of ASXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:ASXC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Asensus Surgical (ASXC) Stock Price, News & Analysis

Asensus Surgical MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Asensus Surgical Stock (NYSEAMERICAN:ASXC)

ASXC Stock Price History

ASXC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ASXC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™